BOARD OF DIRECTORS

Florian Brand – Director

Florian is co-founder and CEO of ATAI Life Science, AG and Interim CEO of its portfolio company Perception Neuroscince. He is also a co-founder and former Managing Director of Springlane. Florian has previous experience with Rocket Internet, Allianz and with the Tanzanian German Program to Support Health where he has held a variety of management positions. He has a Masters in Management from ESCP Europe, background in economics (HEC Lausanne) and Bachelor of Science (BSc), Economics (Ludwig-Maximilians Universität München).

Richard G Farrell – Chief Financial Officer

Richard is a former Investment Banker with over 23 years of experience in finance, M&A, capital raises and corporate restructures in Australia and the United States. Richard has been founder and CFO of several companies and was formerly an Investment Banker with Beerworth & Partners in Sydney Australia, where he advised on takeovers and private placements. Prior to that, Richard was with Ernst & Young Corporate Finance and formerly Deloitte Touché Corporate Finance. Richard has a BComm. (Australian National University), LLB (Australian National University) and a Graduate Diploma in Finance & Investment (Finsia).

H. Christian Fibiger, PhD – Independent Director

Dr. Fibiger has held senior positions in biotechnology and pharmaceutical companies. Prior to serving as SVP and Chief Scientific Officer at Biovail, he was VP and Global Head of Neuroscience at Amgen, and VP of Neuroscience Discovery and Clinical Investigation at Eli Lilly and Company. Until 1998, he was Professor and Head of the Division of Neurological Sciences at the University of British Columbia. Dr. Fibiger received his PhD in Psychopharmacology from Princeton University.

Matthias Luz, M.D. – Director

Dr. Luz is Chief Medical Officer at Atai Life Sciences and a board-certified anesthesiologist with more than 26 years in the biopharmaceutical industry. Dr. Luz has extensive experience in preclinical and clinical drug development including regulatory affairs. He previously served as Chief Medical Officer for MedGenesis, with direct responsibility for all of the company’s development activities. Prior to MedGenesis, Dr. Luz was the Vice President and Head, Global Product Development Services for PRA International, and held senior positions at Cardion, Abbott/Knoll, and Aventis/Hoechst Marion Roussel/Behringwerke.

Ian J. Massey D.Phil. – Chief Executive Officer

Dr. Massey has over 30 years of pharmaceutical industry experience in all phases of research and development, from target selection through to NDA approval. Dr. Massey has founded, built and successfully exited several biotech companies. His primary focus has been in small molecule and protein therapeutics in multiple therapeutic areas. Dr. Massey has a D.Phil. from the University of Oxford (England) and performed post-doctoral work with Carl Djerassi at Stanford. He was formerly Head of Research and Early Development at Roche Pharmaceuticals (Palo Alto), founder and CEO of Synosia Therapeutics, President of Biotie Therapeutics and CEO of StemCell Inc.